MIRA INFORM REPORT
|
Report Date : |
25.02.2011 |
IDENTIFICATION DETAILS
|
Name : |
UCB JAPAN CO LTD |
|
|
|
|
Registered Office : |
Ochanomizu Kyoun Bldg 12F, 2-2 Kanda-Surugadai Chiyodaku |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2010 |
|
|
|
|
Date of Incorporation : |
April
1988 |
|
|
|
|
Com. Reg. No.: |
(Tokyo-Chiyodaku) 031534 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceuticals |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
Yen 463.8 Million |
|
Status : |
Satisfactory |
|
Payment
Behaviour : |
Regular |
|
Litigation : |
---- |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30, 2010
|
Country Name |
Previous Rating (01.04.2010) |
Current Rating (30.06.2010) |
|
|
a1 |
a1 |
|
Risk Category |
ECGC Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name
UCB JAPAN CO LTD
REGD NAME
UCB
MAIN OFFICE
Ochanomizu Kyoun Bldg
12F, 2-2 Kanda-Surugadai Chiyodaku
Tel:
03-5283-1800 Fax: 03-5283-1862
URL: www.ucb.com
E-mail: info@ucb.com
ACTIVITIES
Mfg of
pharmaceuticals
BRANCHES
OVERSEAS
FACTORIES
Saitama
OFFICER(S)
EMANUEL
KAYMACKS, PRES (Only phonetically spelled)
Yen
Amount: In million Yen, unless
otherwise stated
SUMMARY
FINANCES FAIR A/SALES Yen 25,600 M
PAYMENTS REGULAR CAPITAL Yen
3,499 M
TREND STEADY WORTH Yen
11,024 M
STARTED 1 988 EMPLOYES 320
COMMENT
MFR OF
PHARMACEUTICALS, WHOLLY OWNED BY UCB SA,
FINANCIAL SITUATION CONSIDERED
FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS
MAX
CREDIT LIMIT: YEN 463.8 MILLION, 30 DAYS NORMAL TERMS
HIGHLIGHTS
The subject company was established by UCB SA,
FINANCIAL INFORMATION
Financials are only partially disclosed.
The sales volume for Dec/2009 fiscal term amounted to Yen 25,600
million, an 8% up from Yen 23,700 million in the previous term. The net profit was posted at Yen 1,900
million, compared with Yen 1,500 million a year ago. .
For the term that ended Dec 2010 the net profit was projected at Yen
1,950 million, on a 4% rise in turnover, to Yen 26,500 million. Final results are yet to be released.
The financial situation is considered FAIR and good for ORDINARY
business engagements. Max credit limit
is estimated at Yen 463.8 million, on 30 days normal terms.
REGISTRATION
Date Registered: Apr
1988
Regd No.: (Tokyo-Chiyodaku) 031534
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 69,980 shares
Issued: 69,980 shares
Sum: Yen
3,499 million
Major shareholders (%): UCB
SA (
Nothing
detrimental is known as to the commercial morality of executives.
OPERATION
Activities: Manufactures
allergic cure medicines centrally (--100%)
Clients: [Mfrs,
wholesalers] Daiichi Sankyo Co (30%), Glaxo Smith Kline KK (30%), Taiho
Pharmaceutical, Kissei Pharmaceutical Co, other
No. of accounts: 500
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs] Farchim
UCB, other
Payment record: Regular
Location: Business area in
Bank References:
· SMBC (Ningyocho)
· MUFG (Kanda)
Relations:
Satisfactory
FINANCES
(In Million Yen)
|
Terms Ending: |
|
31/12/2010 |
31/12/2009 |
31/12/2008 |
31/12/2007 |
|
Annual
Sales |
|
26,500 |
25,600 |
23,700 |
26,800 |
|
Recur.
Profit |
|
|
|
|
|
|
Net
Profit |
|
1,950 |
1,900 |
1,500 |
836 |
|
Total
Assets |
|
|
N/A |
N/A |
N/A |
|
Net
Worth |
|
|
11,024 |
9,524 |
8,024 |
|
Capital,
Paid-Up |
|
|
3,499 |
3,499 |
3,499 |
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
3.52 |
8.02 |
-11.57 |
-7.95 |
|
|
Current Ratio |
|
|
.. |
.. |
.. |
|
N.Worth Ratio |
|
.. |
.. |
.. |
|
|
N.Profit/Sales |
7.36 |
7.42 |
6.33 |
3.12 |
|
Notes:
Financials are only partially disclosed.
Forecast
(or estimated) figures for the 31/12/2010 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.45.37 |
|
|
1 |
Rs.73.54 |
|
Euro |
1 |
Rs.62.39 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.